Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by UroGen Pharma Ltd.
< Previous
1
2
3
Next >
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
December 01, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference
November 21, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma
November 14, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 10, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors
November 09, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
November 03, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
October 11, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution
September 28, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors
September 12, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Upcoming 2022 Conferences
September 07, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
August 11, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
July 27, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at Upcoming Investor Conferences
May 18, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer
May 16, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
May 13, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 10, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
May 03, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
March 29, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
March 21, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference
February 28, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients
February 10, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
February 03, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at Upcoming Conferences
January 05, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
December 21, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
November 15, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Upcoming 2021 Conferences
November 11, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
November 10, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.